Show simple item record

dc.contributor.authorHawkins, ER
dc.contributor.authorD'Souza, RR
dc.contributor.authorKlampatsa, A
dc.date.accessioned2021-06-10T15:22:39Z
dc.date.available2021-06-10T15:22:39Z
dc.identifier.citationBiologics : targets & therapy, 2021, 15 pp. 95 - 105
dc.identifier.issn1177-5475
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4604
dc.identifier.eissn1177-5491
dc.identifier.eissn1177-5491en_US
dc.identifier.doi10.2147/btt.s291768
dc.identifier.doi10.2147/btt.s291768en_US
dc.description.abstractChimeric antigen receptor (CAR) T-cell therapy engineers T-cells to express a synthetic receptor which redirects effector function to the tumor, to improve efficacy and reduce toxicities associated with conventional treatments, such as radiotherapy and chemotherapy. This approach has proved effective in treating hematological malignancies; however, the same effects have not been observed in solid tumors. The immunosuppressive tumor microenvironment (TME) creates a significant barrier to solid tumor efficacy and reduces the anti-cancer activity of endogenous tumor-resident immune cells, enabling cancer progression. In recent years, researchers have attempted to enhance CAR T-cell function in the TME by engineering the cells to express various proteins alongside the CAR. Examples of this engineering include inducing CAR T-cells to secrete cytokines or express cytokine receptors to modulate the cytokine milieu of the TME. Alternatively, the CAR T-cell may secrete antibody-like proteins to target a range of tumor antigens. Collectively, these methods are termed armored CAR T-cell therapy, and in this review, we will discuss the range of armored CAR T-cell approaches which have been investigated to date.
dc.formatElectronic-eCollection
dc.format.extent95 - 105
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0
dc.titleArmored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy.
dc.typeJournal Article
dcterms.dateAccepted2021-04-06
rioxxterms.versionVoR
rioxxterms.versionofrecord10.2147/btt.s291768
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc/4.0
dc.relation.isPartOfBiologics : targets & therapy
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Thoracic Oncology Immunotherapy Group (TOIG)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Thoracic Oncology Immunotherapy Group (TOIG)
pubs.publication-statusPublished
pubs.volume15en_US
pubs.embargo.termsNot known
icr.researchteamThoracic Oncology Immunotherapy Group (TOIG)
icr.researchteamThoracic Oncology Immunotherapy Group (TOIG)en_US
dc.contributor.icrauthorKlampatsa, Asteroen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc/4.0